# Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

> **NCT01838200** · PHASE1 · TERMINATED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Bacillus Calmette-Guérin (BCG) vaccine
- **DRUG:** Ipilimumab
- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT01838200
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2015-08-17
- **Final completion:** 2015-08-17
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow recruitment due to changes in standard of care
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838200, "Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01838200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*